Smith+Nephew Partners with SI-BONE to Expand Pelvic Fracture Fixation Portfolio
核心洞察
Smith+Nephew (搜索) has signed a distribution agreement with SI-BONE to offer the innovative iFuse TORQ (搜索) portfolio for percutaneous pelvic fracture (搜索) fixation procedures.
The partnership centers on iFuse TORQ TNT (搜索), which received FDA Breakthrough Device Designation for more effective pelvic fracture (搜索) treatment compared to traditional cannulated screws.
The collaboration expands Smith+Nephew (搜索)'s trauma portfolio and strengthens its position in high-frequency, high-impact trauma procedures through SI-BONE's established technology platform.
Smith+Nephew (搜索), the global medical technology company, announced on February 23, 2026, that it has signed a distribution agreement with SI-BONE focused on their innovative iFuse TORQ (搜索) portfolio. This strategic collaboration expands Smith+Nephew's portfolio offerings for percutaneous pelvic fracture (搜索) fixation procedures and strengthens the company's position in high-frequency, high-impact trauma procedures.
"We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder at Smith+Nephew (搜索). "This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE's industry leadership with Smith+Nephew's established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth."
Advanced Technology Platform
The iFuse TORQ (搜索) portfolio includes iFuse TORQ TNT (搜索) and iFuse TORQ implants, offering breakthrough solutions with indications for pelvic fracture (搜索) fixation and fusion of the sacroiliac (SI) joint. iFuse TORQ TNT is designed specifically to address the anatomical and bone density needs of the sacrum (搜索) and ilium (搜索), representing the next generation of technology for pelvic fracture fixation and SI joint fusion.
The technology provides significant market advantages through regulatory recognition and reimbursement benefits. iFuse TORQ TNT (搜索) has received FDA Breakthrough Device Designation, recognized for its potential to provide more effective treatment of pelvic fractures compared to traditional cannulated screws. Additionally, the device is eligible for a Medicare New Technology Add-on Payment, which may provide up to $4,136 in additional reimbursement per procedure for hospitals using iFuse TORQ TNT.
Strategic Market Position
Smith+Nephew (搜索) will have access to the broader iFuse TORQ (搜索) portfolio alongside SI-BONE's current sales channel, expanding the ability to serve surgeons and patients in this high-need area. The partnership aligns with Smith+Nephew's disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients.
SI-BONE has established itself as a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy-specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. Since 2009, SI-BONE has supported physicians in performing over 140,000 procedures, backed by a unique body of clinical evidence that includes four randomized controlled trials and over 180 peer-reviewed publications.
Company Profiles
Smith+Nephew (搜索) operates as a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue across three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, UK, in 1856, the company now operates in more than 100 countries with 18,000 employees and generated annual sales of $5.8 billion in 2024.
SI-BONE continues to leverage its deep experience in addressing the challenges of low-density bone in the sacrum (搜索) to develop unique technologies targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. The company trades on NASDAQ under the symbol SIBN and maintains its focus on biomechanical design and anatomy-specific innovation within the spinopelvic anatomy space.